● Recruiting

Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Condition: Philadelphia Chromosome-Positive · Acute Lymphoblastic Leukemia · Sponsor: M.D. Anderson Cancer Center

PhasePhase 1/Phase 2

Planned participants40

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.

This description comes directly from the study's public registry record.

Talk to the study team

Nicholas Short, MD · (713) 563-4485 · nshort@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (2)

Montefiore Einstein Comprehensive Cancer Center	The Bronx, New York, United States	Not Yet Recruiting
MD Anderson Cancer Center	Houston, Texas, United States	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06308588